Skip to main content
. Author manuscript; available in PMC: 2015 Apr 1.
Published in final edited form as: Mol Cancer Res. 2014 Jan 27;12(4):550–559. doi: 10.1158/1541-7786.MCR-13-0458

Figure 5. Pharmacologic inhibition of Mcl-1 inhibits NSCLC cell growth.

Figure 5

(A) H1975 cells were grown in the presence or absence of TWEAK (100 ng/mL) and EU-5148 (10µM). Cells were lysed and immunoprecipitated with anti-Bak antibodies. Protein expression Mcl-1, Bcl-xL and Bak after immunoprecipitation were resolved by immunoblot analysis. (B) Cell viability of DHL10, Bcl-2 1863 and Mcl-1 1780 cells was assessed by PrestoBlue assay. Cells were exposed to the indicated concentrations of EU-5148 in DMSO for 48 hours. Cell killing curves and EC-50 values were generated from triplicate runs in GraphPad Prism 5. (C) A panel of NSCLC cell lines was exposed to vehicle or 10 µM EU-5148 for 48 hours. Cell growth was assessed by Cell-Titer Glo assay. Bars represent the average of two wells with the untreated set to 100%.